The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (584.93) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -543.6%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 543.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.2% - 6.6% | 5.9% |
| Long-term Growth Rate | 3.0% - 4.9% | 4.0% |
| Fair Price | (4,445.66) - (315.65) | (584.93) |
| Upside | -3471.2% - -339.4% | -543.6% |